natgillin/translations-raw huggingface dataset:
24-month mechanistic study in male rats demonstrated that administration of pioglitazone resulted in an increased incidence of hyperplastic changes in the bladder.
24-mesečna študija mehanizma pri samcih podgan je pokazala, da se pri uporabi pioglitazona poveča pojavnost hiperplastičnih sprememb v sečnem mehurju.
24-Week
inusitis
24-week arm
24-tedenska skupina
24.4 months
95-% CI
24.4 months 19.3 - 30.7
24,4 meseca
24.7b
24,7
24/6 mg daily + Victrelis 800 mg
na dan + zdravilo Victrelis 800 mg trikrat na dan
24/6 mg)/ Elvitegravir (150 mg once daily)/ Cobicistat (150 mg once daily)
24/6 mg)/elvitegravir (150 mg enkrat dnevno)/kobicistat (150 mg enkrat dnevno)
240 (122 mild, 99 moderate, 15 severe)a
240 (122 blaga, 99 zmerna, 15 huda)a
240 capsules
240 kapsul
240 h
240 ur
240 mg twice a day.
240 mg dvakrat na dan.
240 ml oral solution
240 ml peroralne raztopine
240 ml oral suspension
240 ml peroralne suspenzije
240 patients, who had previously completed the 12-month RESTORE study, were enrolled in the open-label, multicentre
240 bolnikov, ki so že zaključili 12-mesečno zdravljenje v študiji RESTORE, so vključili v odprto multicentrično
2400 (3 x 20 cartridges x 40) tablets (multipack)
2400 (3 x 20 vložki x 40) tablet (skupno pakiranje)
2400 IU
2400 i.e.
2400 IU*** human von Willebrand factor** (VWF)
2400 i.e.*** humanega von Willebrandovega faktorja** (VWF).
240ml (120 doses)
240 ml (120 odmerkov)
240ml (120 doses)
240ml (120 odmerkov)
24106 Kiel GERMANY
24106 Kiel NEMČIJA
24106 Kiel GERMANY
Nemčija
242 137 65 28 12 1 0
DACOGEN 242 137 65 28 12 1 0
2440 Geel Belgium
2440 Geel Belgija
245 mg/61.25 mg modified-release hard capsule
245 mg/61,25 mg trda kapsula s prirejenim sproščanjem
245 mg/61.25 mg modified-release hard capsules
245 mg/61,25 mg trda kapsula s prirejenim sproščanjem
245 mg/61.25 mg, or 390 mg/97.5 mg, three times a day.
245 mg/61,25 mg ali 390 mg/97,5 mg, trikrat na dan.
2491 Neufeld / Leitha Austria
2491 Neufeld/Leitha Avstrija
24x1 capsules + 1 inhaler.
24x1 kapsula + 1 inhalator.
25 ampoules
25 ampul
25 capsules
25 kapsul
25 days after the first dose, administer Zycortal, as follows:
25 dni po prvem odmerku dajte zdravilo Zycortal kot sledi:
25 doses
1 x 25 odmerki
25 doses
25 od- merkov
25 doses (50 ml).
25 odmer ki (50 ml)
25 doses = 50 ml vial.
2 ml = 1 odmerek, 25 odmerkov = 50 ml steklena viala.
25 doses for gilts and sows, 100 doses for piglets
25 odmerkov za mladice in svinje, 100
25 doses for gilts and sows, 100 doses for piglets
25 odmerkov za mladice in svinje, 100 odmerkov za pujske
25 doses for gilts and sows, 100 doses for piglets
25 odmerkov za mladice in svinje, 100 odmerkov za pusjke
25 glass containers + 25 oral applicators + 25 transfer adapters
25 steklenih vsebnikov + 25 peroralnih aplikatorjev + 25 nastavkov za prenos
25 inhalers
25 inhalatorjev
25 inhalers
EU/1/13/862/007
25 inhalers
EU/1/13/863/007
25 inhalers
EU/1/14/917/007
25 kg to less than 30 kg
od 25 kg do manj kot 30 kg
25 mg BIW
25 mg 2x/ted en
25 mg BIW
25 mg 2x/teden
25 mg daily
25 mg na dan
25 mg dl-α-tocopheryl acetate 346 mg light liquid paraffin.
25 mg dl-α-tokoferil acetata 346 mg redko tekočega parafina
25 mg dose — 1 sachet
odmerek 25 mg — 1 vrečica
25 mg Enbrel or placebo were administered subcutaneously twice a week for 6 consecutive months.
6 mesecev zapovrstjo 2-krat tedensko subkutano injicirali odmerke zdravila Enbrel po 10 mg ali 25 mg ali placebo.
25 mg film-coated tablets: polyvinyl alcohol, titanium dioxide (E171), macrogol 3350, talc, iron oxide yellow (E172), iron oxide black (E172).
25 mg filmsko obložene tablete: polivinilalkohol, titanov dioksid (E171), makrogol 3350, smukec, rumeni železov oksid (E172), črni železov oksid (E172).
25 mg hard capsules Capsule content Mannitol (E421) Croscarmellose sodium Povidone (K-25) Magnesium stearate
vsebina kapsule manitol (E421) premreženi natrijev karmelozat povidon (K-25)
25 mg lyophilised powder to be reconstituted with 5 ml sodium chloride 9 mg/ml (0.9%) solution for injection before administration.
Pred dajanjem 25 mg liofiliziranega praška rekonstituiramo s 5 ml 9 mg/ml (0,9%) raztopine natrijevega klorida za injiciranje.
25 mg of dry, lyophilised powder in an atmosphere of sulphur hexafluoride in a colourless Type I glass vial, with elastomeric closure.
25 mg suhega, liofiliziranega praška v atmosferi žveplovega heksafluorida v brezbarvni viali iz stekla tipa I, z zamaškom iz gume.
25 mg once daily on days 1-21, every 28 days
25 mg enkrat na dan od 1. do 21. dne, vsakih 28 dni
25 mg suspension for injection
25 mg suspenzija za injiciranje
25 mg/day, Days 1 to 21 every 28 days plus dexamethasone 40 mg/day on Days 1 to 4, 9 to 12, and 17 to 20 every 28 days for the first four cycles.
21. dne vsakih 28 dni plus deksametazon 40 mg/dan od 1. do 4, dne,od 9. do 12. dne in od 17. do 20. dne vsakih 28 dni prve štiri cikle.
25 mg/day, Days 1 to 21 every 28 days plus dexamethasone 40 mg/day on Days 1 to 4, 9 to 12, and 17 to 20 every 28 days for the first four cycles.
21. dne vsakih 28 dni plus deksametazon 40 mg/dan od 1. do 4. dne, od 9. do 12. dne in od 17. do 20. dne vsakih 28 dni prve štiri cikle.
25 mg/kg feed) effectively prevented the development of the disease.
25 mg/kg krme) učinkovito preprečilo razvoj bolezni.
25 mg/kg feed) was effective in controlling the clinical signs and prevented weight loss caused by the disease in untreated pigs.
25 mg/kg krme) učinkovito pri uravnavanju kliničnih znakov in preprečevanju izgube telesne mase, ki jo povzroča bolezen pri nezdravljenih prašičih.
25 mg: -44.6 mg/dl; add-on to metformin plus sulphonylurea, placebo: -2.3 mg/dl, empagliflozin 10 mg: -35.7 mg/dl, empagliflozin 25 mg: -36.6 mg/dl).
24. tednu (dodatno zdravljenje k metforminu, placebo +5,9 mg/dl, empagliflozin 10 mg: -46,0 mg/dl, empagliflozin 25 mg: -44,6 mg/dl, dodatno zdravljenje k metforminu s sulfonilsečnino: placebo -2,3 mg/dl, empagliflozin 10 mg: -35,7 mg/dl, empagliflozin 25 mg: -36,6 mg/dl).
25 mg: 14 and 28 orodispersible tablets
25 mg: 14 in 28 orodisperzibilnih tablet
25 microgram/ml solution
25 mikrogramov/ml
25 micrograms Hepatitis B surface antigen ** ................................................
25 mikrogramov Površinski antigen virusa hepatitisa B **...............................
25 micrograms Purified pertussis filamentous haemagglutinin ......................
Prečiščen filamentozni hemaglutinin bordetele pertusis........
25 million
18 milijonov
25 million
25 milijonov
25 million IU/2.5 ml solution for injection 1 multiple dose vial
25 milijonov i.e./2,5 ml raztopina za injiciranje 1 viala z večkratnimi odmerki
25 million IU/2.5mL
25 milijonov
25 ml BOTTLE LABEL
NALEPKANA 25 ml STEKLENICI
25 mm (1 inch) 23 gauge
25 mm, velikost 23
25 modified-release hard capsules 100 modified-release hard capsules 240 modified-release hard capsules
25 trdih kapsul s prirejenim sproščanjem 100 trdih kapsul s prirejenim sproščanjem 240 trdih kapsul s prirejenim sproščanjem
25 multidose containers (100 doses)
(100 odmerkov)
25 oral applicators
25 peroralnih aplikatorjev
25 patients (aged 13-69 years) participated in the pharmacokinetic (PK) assessment.
Petindvajset bolnikov (starih od 13–69 let) je sodelovalo v farmakokinetični oceni.
25 picogram/ml).
25 pikogramov/ml).
25 PREFILLED SYRINGES WITH 25 NEEDLES
25 NAPOLNJENIH INJEKCIJSKIH BRIZG Z 25 IGLAMI
25 PREFILLED SYRINGES WITHOUT NEEDLE
25 NAPOLNJENIH INJEKCIJSKIH BRIZG BREZ IGEL
25 single dose vials
25 enoodmernih vial
25 single doses 0.5 ml pre-filled syringes with attached needle.
25 posameznih odmerkov po 0,5 ml v napolnjenih injekcijskih brizgah z iglo.
25 to 50 mg / day*
25 do 50 mg/dan
25 to < 32.5
25 do < 32.5
25 VIALS
25 VIAL
25 vials lyophilisa te + 25 vials solvent
25 vial liofilizata + 25 vial vehikla
25 x 1 dose
25 x 1 odmerek
25 x 1 dose (1 ml)
25 x 1 odmerek (1 ml)
25 x 1 dose (1 ml)
5 x 1 odmerek (1 ml)
25 x 2 ml ampoules 5 x 2 ml vials 4 x 4 ml vials 4 x 10 ml vials
25 x 2 ml ampule 5 x 2 ml viale 4 x 4 ml viale 4 x 10 ml viale
25 µg Hepatitis B surface antigen.....................................................................
25 µg Površinski antigen virusa hepatitisa B ....................................................
25% insulin lispro and 75% insulin lispro protamine suspension (rDNA origin)
Suspenzija 25 % insulina lispro in 75 % insulina lispro-protamin (izdelanih s pomočjo rekombinantne
25% insulin lispro and 75% insulin lispro protamine suspension (rDNA origin)
Suspenzija 25 % insulina lispro in 75 % insulina lispro-protamin (izdelanih s pomočjo rekombinantne DNA)
25% of the insulin lispro in Humalog Mix25 KwikPen is dissolved in water and it works more quickly than normal human insulin because the insulin molecule has been changed slightly.
25 % insulina lispro v zdravilu Humalog Mix25 KwikPen je raztopljenega v vodi in deluje hitreje kakor običajni humani insulin, ker je ta molekula insulina nekoliko spremenjena.
25% of the insulin lispro in Liprolog Mix25 KwikPen is dissolved in water and it works more quickly than normal human insulin because the insulin molecule has been changed slightly.
25 % insulina lispro v zdravilu Liprolog Mix25 KwikPen je raztopljenega v vodi in deluje hitreje kakor običajni humani insulin, ker je ta molekula insulina nekoliko spremenjena.
25%e (12%, 36%)
25% e (12%, 36%)
25, 50, 100, 200 or 300 ml of solution in a vial (Type I glass) with a stopper (bromobutyl rubber).
25, 50, 100, 200 ali 300 ml raztopine v viali (iz stekla tipa I) z zamaškom (iz bromobutilne gume).
25,000 units
25.000 enot
25-120 hours
25–120 ur
25-desacetyl-rifampicin AUC ↓ 9%
25-deacetil-rifampicin AUC ↓ 9
25-desacetyl-rifampicin Cmin not studied
posakonazola ni
25-O-desacetyl-rifabutin
25-O-deacetil-rifabutin
25-O-desacetyl-rifabutin
rifabutinu in
25-O-desacetyl-rifabutin AUC ↑990%
25-O-dezacetil-rifabutin AUC ↑990% (↑714% ↑1.361%)
25-O-desacetyl-rifabutin Cmax ↑677%
25-O-dezacetil-rifabutin Cmax ↑677% (↑513% ↑883%)
25-O-desacetyl-rifabutin Cmin ↑1045%
25-O-dezacetil-rifabutin Cmin ↑1.045% (↑715% ↑1.510%)
25-O-desacetyl-rifabutin may be expected.
25-O-deacetil-rifabutinu.
25-O-desacetyl-rifabutin: AUC: ↑ 525%
25-O-desacetil-rifabutin: AUC: ↑ 525
25-O-desacetyl-rifabutin:§ AUC: ↑ 851%**
25-O-desacetil-rifabutin:§ AUC: ↑ 851
25-O-desacetylrifabutin Cmax ↑ 3.2
Cmax 25-O-dezacetilrifabutina
25-O-desacetylrifabutin Cmax ↑ 3.2
Cmin 25-O-dezacetilrifabutina
25-O-desacetylrifabutin Cmin ↑ 7.8
Cmin 25-O-dezacetilrifabutina
25-O-desacetylrifabutin: AUC(0-48)  11-fold*
25-O-dezacetilrifabutin: Cmax6-krat* 25-O-dezacetilrifabutin: AUC(0-48)  11- krat
25.4 ± 9.9
(n = 107)
25.5 months
24,4 meseca
25.6 (8.5) and 29.2 (6.2) mcg h/mL were similar with oral and IV administration of tedizolid phosphate, respectively.
2,2 (0,6) oziroma 3,0 (0,7) µg/ml in vrednosti AUC 25,6 (8,5) oziroma 29,2 (6,2) µg·h/ml.
25.6 (8.5) and 29.2 (6.2) mcg·h/mL were similar with oral and IV administration of tedizolid phosphate, respectively.
2,2 (0,6) oziroma 3,0 (0,7) µg/ml in vrednosti AUC 25,6 (8,5) oziroma 29,2 (6,2) µg·h/ml.
25.8
vrednost
250
po
250 capsules
250 kapsul
250 International Units/vial simoctocog alfa (100 IU/ml after reconstitution)
250 mednarodnih enot/vialo simoktokog alfa (100 i.e./ml po rekonstituciji)
250 IU (octocog alfa) (100 IU/mL after reconstitution).
250 a.e. (októkóg alfa) (100 a.e./ml eftir blöndun).
250 IU /
250 i.e. /
250 IU moroctocog alfa for single IV use
250 i.e. moroktokoga alfa za enkratno i.v. uporabo
250 IU octocog alfa
250 i.e. oktokoga alfa
250 IU octocog alfa (100 IU/ml after reconstitution).
250 i.e. oktokoga alfa (po rekonstituciji 100 i.e./ml).
250 IU* human coagulation factor VIII** (FVIII).
250 i.e.* humanega koagulacijskega faktorja VIII** (FVIII).
250 IU/mL after reconstitution)
250 i.e./ml po rekonstituciji)
250 IU/ml after reconstitution)
250 i.e./ml po rekonstituciji).
250 IU/vial
250 i.e./vialo
250 mcg (8 m IU) per ml after reconstitution
250 mikrogramov (8,0 milijonov i.e.)/ml po rekonstituciji
250 mg (5 sachetsa)
250 mg (5 vrečica)
250 mg (5 sachetsb)
250 mg (5 vrečicb)
250 mg film-coated tablets: brilliant blue FCF (E133) and indigotine (E132).
250 mg filmsko obložene tablete: briljantno modro FCF (E133) in indigotin (E132).
250 mg qid
250 mg štirikrat na dan
250 mg sachets
250-mg vrečice
250 mg single
odmerek
250 mg tablet: Indigo carmine (E132).
250 mg tableta: indigotin (E132)
250 mg telavancin (as hydrochloride) per vial
250 mg telavancina (v obliki klorida) na vialo
250 mg twice daily
250 mg dvakrat na dan 22
250 mg: 20, 30, 50, 60, 100 and multipack of 200 (2 packs of 100) film-coated tablets.
250 mg: 20, 30, 50, 60, 100 ali skupno pakiranje po 200, ki vsebuje (2 pakiranji po 100) filmsko obloženih tablet.
250 mg: 20, 30, 50, 60, 100 x 1, 100 film-coated tablets and multipacks containing 200 (2 packs of 100) film-coated tablets
250 mg: 20, 30, 50, 60, 100 x 1, 100 filmsko obloženih tablet in v večkratnem pakiranju po 200 (2 pakiranji po 100) filmsko obloženih tablet.
250 micrograms (n= 185)
250 mikrogramov (n = 185)
250 micrograms (n= 189)
250 mikrogramov (n = 189)
250 micrograms (n= 223)
250 mikrogramov (n = 223)
250 micrograms of r-hCG or 5,000 to 10,000 IU of hCG, 24 to 48 hours after the last Ovaleap injection.
250 mikrogramov r-hCG ali 5.000 do 10.000 i.e. hCG, 24 do 48 ur po zadnji injekciji zdravila Ovaleap.
250 micrograms of r-hCG or 5,000 to 10,000 IU of hCG, 24 to 48 hours after your last Ovaleap injection.
250 mikrogramov r-hCG ali 5.000 do 10.000 i.e. hCG, 24 do 48 ur po zadnji injekciji zdravila Ovaleap.
250 micrograms PRE-FILLED SYRINGES LABEL
NALEPKA ZA NAPOLNJENO INJEKCIJSKO BRIZGO 250 mikrogramov
250 ml
250 m
250 ml (1000 doses)
250 ml (1000 odmerkov)
250 ml (125 doses
250 ml (125 odmerkov
250 ml amber glass bottle with a yellow collar on the neck, sealed with a poly-seal cap, and secured with PET film.
250-ml Type III rjava steklenica z rumeno ovratnico na vratu, zaprta s poli-tesnilno zaporko in zavarovana s PET folijo.
250 ml oral solution 500 ml oral solution
250 ml peroralne raztopine 500 ml peroralne raztopine
250 ml Sodium Chloride 9 mg/ml (0.9%)
250 ml natrijev klorid 9 mg/ml (0,9 %)
250 ml white HDPE bottle with child-resistant closure containing 270 capsules.
250 ml plastenka bele barve iz polietilena visoke gostote z za otroke varno zaporko; vsebuje 270 kapsul.
250 mL, at a free flowing rate to flush the vein.
250 ml, s prostim tokom za spiranje vene.
250 or 500 ml multidose glass bottle 250 or 500 ml multidose PET bottle
Večodmerna steklenička po 250 ali 500 ml Večodmerna plastenka iz PET po 250 ali 500 ml
250 pigs with an average bodyweight of 20 kg).
250 prašičev s povprečno telesno težo 20 kg).
250, 500, 1000, 1500, 2000 or 3000 IU).
250, 500, 1000, 1500, 2000 ali 3000 i.e.).
250-499 cells/mm3: Week 1-2 - interrupt dosing until >750 cells/mm3 then resume dose with a 2 level adjustment; Week 3-48 - interrupt dosing until >750 cells/mm3 then resume dose with a 1 level adjustment.
250 – 499 celic/mm3: 1.-2. teden – prekinitev odmerjanja, dokler ni doseženo > 750 celic/mm3, nato nadaljevanje z zmanjšanim odmerkom za 2 stopnji; 3.-48. teden – prekinitev odmerjanja dokler > 750 celic/mm3, nato nadaljevanje z zmanjšanim odmerkom za 1 stopnjo.
2500 C. PecFent 400 µg dose D. PecFent 800 µg dose
PecFent 800 µg odmerek
2500 doses
2.500 odmerkov
2500 IU
2500 i.e.
2500 mg/m2 total daily dose) for 14 days followed by a 7-day rest period.
1.250 mg/m2 dvakrat na dan (zjutraj in zvečer; celokupni dnevni odmerek znaša 2.500 mg/m2) 14 dni, sledi 7-dnevni premor.
2500 Valby Denmark.
2500 Valby Danska
251 [111, 572]
Miokardni infarkt
252 tablets
252 tablet
252 x 1 capsules (unit dose)
252 x 1 kapsul (odmerek enote)
252.0 micrograms
252,0 mikrogramov
253 6.6% vs 9.8%
ROG 0,83
254
po
254 patients with normal hepatic function (total bilirubin ≤ULN and AST ≤ULN), ceritinib exposures were similar in patients with mild hepatic impairment and normal hepatic function.
≤ ZMN) je bila izpostavljenost ceritinibu pri bolnikih z blago okvaro jeter približno enaka kot pri bolnikih z normalnim delovanjem jeter.
25436 Uetersen GERMANY
25436 Uetersen NEMČIJA
255 patients who received docetaxel in combination with capecitabine.
255 bolnikih, ki so dobivali docetaksel v kombinaciji s kapecitabinom;
255 patients who received docetaxel in combination with capecitabine.
255 bolnikih, ki so prejemali docetaksel v kombinaciji s kapecitabinom.
256 patients were randomised to treatment with docetaxel alone (100 mg/ m2 as a 1 hour intravenous infusion every 3 weeks).
256 bolnic so naključno razvrstili na zdravljenje s samim docetakselom (100 mg/m2 v enourni intravenski infuziji na 3 tedne).
256 patients were randomised to treatment with docetaxel alone (100 mg/m2 as a 1 hour intravenous infusion every 3 weeks).
256 bolnikov, randomizirano vključenih v preskušanje, je prejemalo le docetaksel (100 mg/m2 v obliki enourne intravenske infuzije vsake 3 tedne).
258 patients who received docetaxel in combination with doxorubicin.
258 bolnikih, ki so dobivali docetaksel v kombinaciji z doksorubicinom;
258 patients who received docetaxel in combination with doxorubicin.
258 bolnikih, ki so prejemali docetaksel v kombinaciji z doksorubicinom.
25–75 percentile (months)
25–75 percentila (meseci)
26 August 2013
26. avgust 2013
26 relevant cases with positive dechallenge after discontinuation or dose reduction or positive rechallenge were identified.
Odkrili so 26 primerov, pri katerih je prišlo do okrevanja po prekinitvi zdravljenja ali znižanju odmerka oziroma do ponovitve simptomov po ponovni uvedbi zdravila.
26 relevant cases with positive dechallenge after discontinuation or reduction of dose or positive dechallenge were identified.
Odkrili so 26 primerov, pri katerih je prišlo do okrevanja po prekinitvi zdravljenja ali znižanju odmerka oziroma do ponovitve simptomov po ponovni uvedbi zdravila.
26 Rue de la Chapelle 68330 Huningue FRANCE
26 Rue de la Chapelle F-68330 Huningue FRANCIJA
26 Rue de la Chapelle F-68330 Huningue France
Elanco France S.A.S 26 Rue de la Chapelle F-68330 Huningue Francija
26 week endpoint
26 (23,2)
26 week endpoint
26. tednu
26 week endpoint
v 26. tednu
26 weeks
24 tednov
26 weeks
28 tednov
26 weeks
52 tednov
26, Rue de la Chapelle 68330 Huningue FRANCE
26, Rue de la Chapelle 68330 Huningue FRANCIJA
26, Rue de la Chapelle 68330 Huningue France
Elanco France S.A.S. 26, Rrue de la Chapelle 68330 Huningue Francija
26,167 unvaccinated Aged ≥7 months Received 3 doses
26.167 necepljenih starih ≥ 7 mesecev prejeti 3 odmerki
26.4% (20.9 to 32.4)
26,4 % (20,9 do 32,4)
26.7%
N/A
260 mg
Odmerek (mg)
26169 Friesoythe Germany
26169 Friesoythe Nemčija
263mg
intramuskularna
264 (82.5)a,b
PBO (N=361)
266 g + 3 dosing spoons
266 g zrnc + 3 merilne žličke
266 g granules
266 g zrnc
2674-506 Loures Portugal
2674-506 Loures Portugalska
268 mg fipronil,
Pipeta (plastika/alu/ plastika)
27 (1.0)
GVT
27 mg once daily
27 mg enkrat na dan
27 to 32) on Day 25, adjust the dose based on the Day 10 Na⁺/K⁺ ratio using the guidelines in Table 1, below.
27 do 32), prilagodite odmerek na podlagi razmerja Na⁺/K⁺ na 10. dan s pomočjo smernic v spodnji preglednici 1.
27% (n = 158)
27 % (n = 158)
27.0 vs.
27,0 v primerjavi z 8,0
27.3 to 30.8
27,3 do 30,8
27.5 micrograms/spray
27,5 mikrogramov/vpih
27.51 months, 62.9 % of patients randomized to the bosutinib arm and 71.3% of patients randomized to the imatinib group were still receiving first-line treatment.
27,51 meseca je 62,9 % bolnikov v skupini z bosutinibom in 71,3 % bolnikov v skupini z imatinibom še vedno prejemalo zdravljenje v prvi liniji.
270 capsules
270 kapsul
270 hard capsules
270 trdih kapsul
270 tablets
270 tablet
270 tablets: EU/1/09/579/005
270 tablet: EU/1/09/579/005
270 tablets: EU/1/09/579/011
270 tablet: EU/1/09/579/011
270 tablets: EU/1/09/579/017
270 tablet: EU/1/09/579/017
270 tablets: EU/1/09/580/005
270 tablet: EU/1/09/580/005
270 tablets: EU/1/09/580/011
270 tablet: EU/1/09/580/011
270 tablets: EU/1/09/580/017
270 tablet: EU/1/09/580/017
270 units*
130 enot*.
270 units*.
270 enot*.
270 x 1 blisters (9 pouches)
270 x 1 pretisni omot
270 x 1 blisters (9 pouches) +
270 x 1 pretisni omot
27460 Igoville France
27460 Igoville Francija
27460 Igoville France
27460 Igoville, Francija
27472 Cuxhaven Germany
27472 Cuxhaven Nemčija
2778 South East Side Highway Elkton, Virginia, 22827,
2778 South East Side Highway Elkton, Virginia, 22827
279 (64.6)a
279 (64,6) a
28 (2 blisters of 14)
28 (2 pretisna omota s po 14)
28 (40.0%)
PGA: čisto/minimalnoc
28 (4x7) pre-filled syringes (multipack)
28 napolnjenih injekcijskih brizg
28 August 2015
Datum prve odobritve: 28 avgust 2015
28 buccal tablets
28 bukalnih tablet
28 capsules
(PVC/PCTFE/Al)
28 capsules
28 trdih kapsul
28 capsules
oblika
28 capsules of Lojuxta 10 mg
28 kapsul zdravila Lojuxta 10 mg
28 capsules of Lojuxta 20 mg
28 kapsul zdravila Lojuxta 20 mg
28 capsules of Lojuxta 30 mg
28 kapsul zdravila Lojuxta 30 mg
28 capsules of Lojuxta 40 mg
28 kapsul zdravila Lojuxta 40 mg
28 capsules of Lojuxta 5 mg
28 kapsul zdravila Lojuxta 5 mg
28 capsules of Lojuxta 60 mg
28 kapsul zdravila Lojuxta 60 mg
28 coated tablets
28 obloženih tablet
28 day pack containing:
28-dnevno pakiranje, ki vsebuje:
28 day pack: 112 capsules (4 blister cards of 21 x 20 mg capsules and 7 x 80 mg capsules) for the 140 mg daily dose for a 28 day supply.
28-dnevno pakiranje: 112 kapsul (4 pretisne zgibanke z: 21 x 20 mg kapsulami in 7 x 80 mg kapsulami) za odmerek 140 mg na dan, zaloga za 28 dni.
28 day pack: 56 capsules (4 blister cards of 7 x 20 mg capsules and 7 x 80 mg capsules) for the 100 mg daily dose for a 28 day supply.
28-dnevno pakiranje: 56 kapsul (4 pretisne zgibanke s: 7 x 20 mg kapsulami in 7 x 80 mg kapsulami) za odmerek 100 mg na dan, zaloga za 28 dni.
28 day pack: 84 capsules (4 blister cards of 21 x 20 mg capsules) for the 60 mg daily dose for a 28 day supply.
28-dnevno pakiranje: 84 kapsul (4 pretisne zgibanke z: 21 x 20 mg kapsulami) za odmerek 60 mg na dan, zaloga za 28 dni.
28 days after first opening.
28 dni po prvem odprtju
28 Days after inactivated vaccinea
28 dni po inaktiviranem cepivua
28 days of treatment with Quinsair 240 mg twice daily followed by 28 days off treatment).
28 dni zdravljenja z zdravilom Quinsair 240 mg dvakrat na dan, ki mu je sledilo 28 dni brez zdravljenja).
28 days.
28 dni.
28 Feb 2021
28. feb.
28 film-coated tablets
28 filmsko obloženih tablet.
28 film-coated tablets
28 x 1 filmsko obložena tableta
28 film-coated tablets
56 x 1 filmsko obložena tableta
28 film-coated tablets (calendar blister)
28 filmsko obloženih tablet (koledarsko pakiranje)
28 film-coated tablets 28x1 film-coated tablets
28 filmsko obloženih tablet 28x1 filmsko obložena tableta
28 film-coated tablets 30x1 film-coated tablets 90x1 film-coated tablets 98 film-coated tablets
90 x 1 filmsko obložena tableta 98 filmsko obloženih tablet
28 film-coated tablets 98 film-coated tablets 500 film-coated tablets
28 filmsko obloženih tablet 98 filmsko obloženih tablet 500 filmsko obloženih tablet
28 film-coated tablets.
26 filmsko obloženih tablet.
28 film-coated tablets.
28 filmsko obloženih tablet
28 hard capsules: EU/1/09/525/008 30 hard capsules: EU/1/09/525/009 56 hard capsules: EU/1/09/525/010 60 hard capsules: EU/1/09/525/011 112 hard capsules: EU/1/09/525/012 200 hard capsules: EU/1/09/525/048 250 hard capsules: EU/1/09/525/013
28 trdih kapsul: EU/1/09/525/008 30 trdih kapsul: EU/1/09/525/009 56 trdih kapsul: EU/1/09/525/010 60 trdih kapsul: EU/1/09/525/011 112 trdih kapsul: EU/1/09/525/012 200 trdih kapsul: EU/1/09/525/048 250 trdih kapsul: EU/1/09/525/013
28 hard capsules: EU/1/09/525/014 30 hard capsules: EU/1/09/525/015 56 hard capsules: EU/1/09/525/016 60 hard capsules: EU/1/09/525/017 112 hard capsules: EU/1/09/525/018 200 hard capsules: EU/1/09/525/049 250 hard capsules: EU/1/09/525/019
28 trdih kapsul: EU/1/09/525/014 30 trdih kapsul: EU/1/09/525/015 56 trdih kapsul: EU/1/09/525/016 60 trdih kapsul: EU/1/09/525/017 112 trdih kapsul: EU/1/09/525/018 200 trdih kapsul: EU/1/09/525/049 250 trdih kapsul: EU/1/09/525/019